Dr. Jelena Dinić

EDUCATION: Ph.D. in Cell biology, The Wenner-Gren Institute, Faculty of Science, Stockholm University, Sweden, 2011. B.Sc. in Molecular biology and physiology, Faculty of Biology, University of Belgrade, 2004.

RESEARCH INTERESTS: Mechanisms of multidrug resistance in cancer and the development of new therapeutics targeting these mechanisms.

WORK EXPERIENCE: Department of Neurobiology, Institute for Biological Research “Siniša Stanković” since 2012. The Wenner-Gren Institute, Stockholm University (2005-2011).

PROJECTS: “Functional diagnostics in non-small cell lung carcinoma−a new concept for the improvement of personalized therapy in Serbian patients” (TargetedResponse,#7739737, 2022-2025), Science Fund of the Republic of Serbia IDEAS; “Biomimetic tumor engineering to enhance drug discovery” (BioengineeredTumor,#7503, 2024-2026), Science Fund of the Republic of Serbia PRISMA; „Biomedical potential of diterpenes newly isolated from latex of milkweeds (Euphorbia L.) wild-growing in Serbia“ (MilkIng, 2022-2025), SASA strategic project; “Innovative hybrid compounds of sclareol and doxorubicin as a new antitumor strategy in glioblastoma therapy” (SCLarDOXInn,2023-2024), SAIGE Proof of concept; “Identification of predictive molecular markers for cancer progression, response to therapy and disease outcome” (#III41031, 2011-2019), Ministry of Education, Science and Technological Development of the Republic of Serbia.

European Cooperation in Science and Technology (COST) Actions: CA22103: A comprehensive network against brain cancer (Net4Brain;2023-2027); IG17104: Pan-European educational platform on multidrug resistant tumours and personalised cancer treatment (PANDORA;2022-2023); CA17104: New diagnostic and therapeutic tools against multidrug resistant tumors (STRATAGEM;2018-2022); CA15138: European network of multidisciplinary research and translation of autophagy knowledge (TRANSAUTOPHAGY;2016-2020); CM1407: Challenging organic syntheses inspired by nature-from natural products chemistry to drug discovery (NATCHEMDRUGS,2015-2019); CM1106: Chemical approaches to targeting drug resistance in cancer stem cells (STEMCHEM;2012-2016).

MEMBERSHIPS IN SCIENTIFIC SOCIETIES: European Association for Cancer Research (EACR), Serbian Association for Cancer Research (SDIR), European Society for Medical Oncology (ESMO), Federation of European Neuroscience Societies (FENS), Serbian Neuroscience Society (DNS), Serbian Biological Society (SBS).